SUMMARY Continuous intravenous infusion of the low molecular weight trypsin inhibitor leupeptin prolonged the survival of rats with acute haemorrhagic pancreatitis (p<O.OO1) compared with controls receiving saline alone. Rats receiving high dose intravenous Trasylol (aprotinin) survived no longer than saline-only controls. Combination therapy of leupeptin with Trasylol conferred no additional benefit over animals treated with leupeptin alone. The nature of the infusion was selected blind after the induction of pancreatitis and survival was quantified by recording of body temperature. These preliminary results suggest that sterically favourable molecules which can complete the inhibition of x2-macroglobulin bound proteinases should contribute to the effective specific chemotherapy of the disease.
It is generally accepted that a crucial event in the pathogenesis of acute necrotising pancreatitis is the overwhelming and inappropriate activation of digestive zymogens within the gland leading to the autodigestion of pancreatic tissue and the massive dissemination of active enzymes. [1] [2] [3] [4] [5] In health such events are prevented by the biosynthesis of inactive precursor forms of the most dangerous enzymes and their storage in membrane-bound granules within the acinar cells. Release of these zymogens into the pancreatic ducts and their subsequent activation only within the gut lumen is a further safeguard. The acinar cell also produces trypsin inhibitors which complex with active free trypsin preventing the protentially disastrous activation of the other proenzymes.' 6 If free trypsin, chymotrypsin, and elastase are released into blood they immediately complex with the serum proteinase inhibitors, ctlantiproteinase and 0t2-macroglobulin.7-10 The olantiproteinase-enzyme complex is catalytically inert but the x2-macroglobulin-enzyme complex retains a proportion of esterolytic and proteolytic activity against substrates of varying molecular size. Normally these complexes are rapidly eliminated from the circulation by the reticuloendothelial * Present address and address for correspondence: Mr P A Jones, Westminster Hospital, London, SWI Received for publication 26 February 1982 system and circulating tryptic activity is insignificant.14 15 The elution profile of partly purified leupeptin on Biogel P2 chromatography is shown in Fig. 1 26 32 This is most likely because of the inability of Trasylol to inhibit the activity of trypsin complexed with os2-macroglobulin due to its failure to gain access to the shielded catalytic site. 18 Susceptible peptide hormones such as glucagon and somatostatin, infused during this period of severe acute pancreatitis will be rapidly degraded by catalytic a2-macroglobulin enzyme complexes against which Trasylol will afford little protection. The use of low-molecular weight anti-proteinase would appear to be advantageous, as they should be independent of these steric constraints. In this study Trasylol was without effect in prolonging the survival of rats with experimental pancreatitis despite its early administration and continuous intravenous infusion at 5 x the recommended clinical dose for man. Intravenous leupeptin resulted in an extension of survival; although this effect was statistically significant, none of the leupeptin treated rats eventually survived. Further studies using highly purified leupeptin are clearly indicated, as residual toxic components may have contributed to mortality in the leupeptin treated animals and certainly limited the dose of the inhibitor that could be used, but these are preliminary findings and form the basis of a continuing study into the use of peptide aldehyde protease inhibitors in the treatment of acute pancreatitis. We would suggest that a combination of different low molecular weight inhibitors, either of bacterial origin or custom synthesised, with a wide spectrum of specificities for the digestive proteases could become an effective treatment for this disease. 
